ERYSO · Engineered erythrocytes and erythrocyte extracellular vesicles for advanced Photodynamic and Sonodynamic therapy
Horizon Europe — Marie Skłodowska-Curie Actions
- Duration
- 2027-01-01 → 2030-12-31
- EU contribution
- €1,788,570
- Participants
- 14
- Scheme
- HORIZON-TMA-MSCA-SE
Lines connect the coordinator with its partners.
Project objective
ERYSO aims to develop innovative therapeutic solutions based on photodynamic (PDT), and sonodynamic (SDT) therapies usingengineered red blood cells (RBCs) and extracellular vesicles (EVs) derived from RBCs in combination with magnetothermal (MHT)therapy. Both RBCs and RBC-derived EVs are characterized by their ability to transport hemoglobin, the body's natural oxygen carrier,and exhibit long circulation times, providing a unique advantage for therapeutic delivery. Encapsulating photosensitizers (PSs) andengineering these carriers for tumor targeting addresses a major limitation of existing PDT and SDT solutions, hypoxic tumor regions, by delivering oxygen directly to these areas, enhancing therapy efficacy. Combining PDT and SDT with MHT further amplifiestherapeutic outcomes, providing a multimodal approach to tumor eradication.Magnetic nanoparticles for MHT or titanium oxide nanoparticles for SDT will be encapsulated in the carriers to enable combination oftherapies. Tumor targeting will be achieved by functionalizing RBC glycocalyx with targeting peptides or incorporating functionalizedlipids into EVs. Enhanced tumor uptake of EVs and RBCs will be facilitated through the Focus Ultrasound (FUS) technique, whichtemporarily permeabilizes the blood-tumor barrier. Tumor targeting and oxygen delivery will be monitored using advancedmolecular imaging techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography(SPECT). Therapeutic efficacy will be evaluated in relevant tumor models, combining molecular imaging and histopathologicalanalysis.The project envisions developing personalized therapies based on autologous patient components, ensuring localized treatmentwith reduced side effects. By leveraging the natural compatibility of RBCs and EVs and integrating cutting-edge targeting and deliverytechnologies, ERYSO advances the potential of personalized and multimodal cancer therapies.
Original text from CORDIS.
Participants
- ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE · San SebastianCoordinatorSpain
- CHULALONGKORN UNIVERSITY · BangkokThailand
- DANUBE PRIVATE UNIVERSITY GMBH · KREMS-STEINAustria
- FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG · ErlangenGermany
- MAHIDOL UNIVERSITY · NAKHON PATHOMThailand
- MAIBE SRL · ROMAItaly
- Prove Innomed Company Limited · NonthaburiThailand
- TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY · HaifaIsrael
- TRAKIYSKI UNIVERSITET · Stara ZagoraBulgaria
- UNIVERSIDAD DE BUENOS AIRES · Buenos AiresArgentina
- UNIVERSIDAD NACIONAL DEL SUR · Bahia BlancaArgentina
- UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA · RomaItaly
- UNIVERSITY OF MAURITIUS · ReduitMauritius
- YAYASAN PERGURUAN TINGGI KRISTEN PETRA · SURABAYAIndonesia
Links
Data: CORDIS, © European Union